Multiple sclerosis: Could Roche’s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS?
Posted:
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of primary progressive multiple sclerosis (PPMS) after allegations that the drug was approved despite internal concerns about its efficacy in women and a potential increased risk of breast cancer.
Helping medical device companies navigate quality, compliance and regulatory pathways with confidence
Bringing a medical device to market requires more than innovative technology. Successful commercialisation depends on robust quality systems, effective risk management and a clear understanding of complex regulatory…
Discover Canada’s healthcare technology leaders connecting with the UK health and life sciences ecosystem
Healthcare innovation is increasingly shaped by international collaboration. By bringing together expertise from different markets, healthcare systems can accelerate the development, validation and adoption of technologies…